CLAIMS

1. A non-sustained release pharmaceutical tablet composition which comprises: a rapidly precipitating drug in an amount from about 5 to about 60%, microcrystalline cellulose, and at least one member selected from the group consisting of a binder in an amount of from about 2 to about 25% and a superdisintegrant in an amount from about 6 to about 40% where the rapidly precipitating drug, microcrystalline cellulose, binder and superdisintegrant are mixed and compressed into a tablet without heating, solvent or grinding.

2. A non-sustained release pharmaceutical tablet composition according to claim 1 where the binder is selected from the group consisting of:

hydroxypropyl methylcellulose,
PVP,
hydroxypropyl cellulose,
methylcellulose,
hydroxyethylcellulose,
carbopol,
sodium carboxymethylcellulose.

3. A non-sustained release pharmaceutical tablet composition according to claim 2 where the binder is hydroxypropyl methylcellulose.

4. A non-sustained release pharmaceutical tablet composition according to claim 2 where the binder is PVP.

5. A non-sustained release pharmaceutical tablet composition according to claim 2 where the binder is present in an amount as follows for:

hydroxypropyl methylcellulose of from about 5 to about 20%,
PVP from about 2 to about 15%,
hydroxypropyl cellulose from about 5 to about 20%,
methylcellulose from about 5 to about 20%,
hydroxyethylcellulose from about 5 to about 20%,
carbopol from about 3 to about 20%,
sodium carboxymethylcellulose from about 3 to about 20%.

6. A non-sustained release pharmaceutical tablet composition according to claim 1 where the superdisintegrant is croscarmellose sodium, sodium starch glycolate, L-hydroxypropyl cellulose.

7. A non-sustained release pharmaceutical tablet composition according to claim 1 where the superdisintegrant is present in an amount of from about 6 to about 35%.

8. A non-sustained release pharmaceutical tablet composition according to claim 7 where the superdisintegrant is present in an amount of from about 10 to about 30%.

9. A non-sustained release pharmaceutical tablet composition according to claim 1 which contains microcrystalline cellulose in an amount up to about 50%.

10. A non-sustained release pharmaceutical tablet composition according to claim 1 where the microcrystalline cellulose is selected from the group consisting of
microcrystalline cellulose coarse powder,
microcrystalline cellulose medium powder and
microcrystalline cellulose 200.

11. A non-sustained release pharmaceutical tablet composition according to claim 9 where the microcrystalline cellulose is microcrystalline cellulose N.F. coarse powder.

12. A non-sustained release pharmaceutical tablet composition according to claim 1 where the microcrystalline cellulose is present in an amount of from about 10 to about 40%.

13. A non-sustained release pharmaceutical tablet composition according to claim 1 which contains lactose in an amount up to about 80%.

14. A non-sustained release pharmaceutical tablet composition according to claim 13 where the lactose is selected from the group consisting of lactose monohydrate spray process standard, lactose monohydrate, lactose anhydrous, lactose dihydrate, DMV lactose.

15. A non-sustained release pharmaceutical tablet composition according to claim 13 where the lactose is N.F. monohydrate spray process standard lactose.

16. A non-sustained release pharmaceutical tablet composition according to claim 12 where the lactose is present in an amount of from about 5 to about 20%.

17. A non-sustained release pharmaceutical tablet composition according to claim 1 which contains a flow agent in an amount up to 5%.

18. A non-sustained release pharmaceutical tablet composition according to claim 17 where the flow agent is selected from the group consisting of colloidal silicon dioxide and talc.

19. A non-sustained release pharmaceutical tablet composition according to claim 17 where the flow agent is colloidal silicon dioxide N.F.

20. A non-sustained release pharmaceutical tablet composition according to claim 1 where the flow agent is present in an amount from 0.25 to about 2%.

21. A non-sustained release pharmaceutical tablet composition according to claim 1 which contains a lubricant in an amount up to 5%.

22. A non-sustained release pharmaceutical tablet composition according to claim 21 where the lubricant is selected from the group consisting of magnesium stearate and stearic acid.

23. A non-sustained release pharmaceutical tablet composition according to claim 21 where the lubricant is magnesium stearate.

24. A non-sustained release pharmaceutical tablet composition according to claim 1 where the lubricant is present in an amount of 0.25 to about 2%.

25. A non-sustained release pharmaceutical tablet composition according to claim 1 where the rapidly precipitating drug is selected from the group consisting of delavirdine mesylate, phenytoin, furosemide, pseudoephedrine, clindamycin hydrochloride, cloridine hydrochloride, diphenhydramine hydrochloride, fluphenazine

hydrochloride, griseofulvin, hydromorphone hydrochloride, naloxone hydrochloride, oxytetracycline hydrochloride, phenylephrine hydrochloride, pheniramine maleate, tetracycline hydrochloride, verapamil hydrochloride, propoxyphene hydrochloride, propoxyphene napsylate, hydrocodine bitartrate, acyclovir sodium, albuterol sulfate, ampicillin sodium, benztropine mesylate, benzphetamine hydrochloride, bupivacaine hydrochloride, bupropin hydrochloride, chlorphenamine maleate, chlorpromazine hydrochloride.

26. A non-sustained release pharmaceutical tablet composition according to claim 1 where the rapidly precipitating drug is present in an amount of from about 10 to about 40%.

27. A non-sustained release pharmaceutical tablet composition according to claim 25 where the rapidly dissolving drug is delavirdine mesylate.

28. A non-sustained release pharmaceutical tablet composition according to claim 27 where the delavirdine mesylate is present in an amount of from about 50 to about 300 mg/tablet.

29. A non-sustained release pharmaceutical tablet composition according to claim 27 where the delavirdine mesylate is present in an amount of about 200 or about 300 mg/tablet.

30. A non-sustained release pharmaceutical tablet composition according to claim 1 which contains both a binder and superdisintegrant.

31. A non-sustained release pharmaceutical tablet composition which is:

Item	Amount (from about to about) %
delavirdine mesylate	10-40
hydroxypropyl methylcellulose	5-20
croscarmellose sodium	6-35
microcrystalline cellulose	10-50
lactose	0-15
colloidal silicon dioxide	0-5
magnesium stearate	0-5

where the delavirdine mesylate, microcrystalline cellulose, hydroxypropyl methylcellulose and croscarmellose sodium are mixed and compressed into a tablet without heating, solvent or grinding.

32. A non-sustained release pharmaceutical tablet composition according to claim 31 which is:

Item	Amount (from about to about) %.
delavirdine mesylate	30.2
hydroxypropyl methylcellulose 2910 U.S.P. 3 cps	11.3
croscarmellose sodium N.F. Type A	16.6
microcrystalline Cellulose N.F. coarse powder	30.0
lactose NF monohydrate spray process standard	10.7
colloidal silicon dioxide N.F.	0.23
magnesium stearate N.F. powder food grade-V bolted	0.76